Navigation Links
Viralytics Full Year Financial Results
Date:9/3/2013

ustralia and the UK)

  • Broad anti-cancer activity of CAVATAK™ demonstrated in preclinical setting.
  • Synergistic effect from the combination of CAVATAK™ and Docetaxel.  Potential combination therapy.
  • Combination with either radiation or chemotherapy resulted in more potent anticancer activity in bladder cancer cell lines than radiation or chemotherapy alone.
  • Potent anti-cancer activity in chronic lymphocytic leukaemia (CLL) cell lines.
  • "The 2013 financial year has been one of outstanding progress at Viralytics, which leaves us well positioned to further develop the business in the coming year," said Dr. Malcolm McColl, Chief Executive Officer of Viralytics. "We have achieved key milestones in our Phase 2 CALM study, with interim results demonstrating promising anti-cancer activity. We also had a number of excellent outcomes in our Phase 1 and preclinical programs, demonstrating the broad anti-cancer activity of CAVATAK™.  Our focus is to maintain momentum in clinical development and translate this progress into valuable commercial outcomes."

    About Viralytics Ltd:
    Viralytics is developing oncolytic virotherapy treatments for a range of cancers.  Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21).  CVA21 binds to specific "receptor" proteins highly expressed on multiple cancer types including, but not limited to melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.  Intratumourally administered CAVATAK™ is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US.  Viralytics also plans to commence a Phase 1/2 study of CAVATAK™ delivered intravenously in patients with melanoma, prostate, lung or metastatic bladder cancers prior to the en
    '/>"/>

    SOURCE Viralytics Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
    2. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
    5. EntreMed Reports Second Quarter 2013 Financial Results
    6. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
    7. Sinovac Reports Unaudited Second Quarter 2013 Financial Results
    8. Vasomedical Announces Financial Results for the Second Quarter of 2013
    9. Nephros Reports Second Quarter 2013 Financial Results
    10. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    11. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... Nov. 26, 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced ... to raise approximately $3.3 million at a price of ... one institutional healthcare focused investor. Each unit consists of one ... share purchase warrant. Each whole warrant entitles the holder ... $0.30 for a period of five years from closing.  ...
    (Date:11/26/2014)... 26, 2014  Cohen, Placitella & Roth, PC ... who purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company") ... from January 31, 2011 through November 2, 2014 ... certain of its officers and directors publically disseminated ... Sections 10(b) and 20(a) of the Securities Exchange ...
    (Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
    Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
    ... Tissue Oncology, Society held in Seattle, Washington demonstrates clinical ... single agent in patients with ... chemo-insensitive sarcomas, NEW YORK, Nov. ... preliminary data demonstrating the,tolerability and clinical activity of KRX-0401 (perifosine) in ...
    ... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
    Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 5Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 6Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3
    (Date:11/28/2014)... Recently, BellasDress , a renowned dress manufacturer in ... line of cocktail dresses. In addition, these fresh dresses are ... free shipping on orders over $179. The aim of the ... is providing many styles of dresses, which come in various ... and more. All of them are on sale at affordable ...
    (Date:11/28/2014)... Recently, PrettyTailor.com has developed and created its ... around the world in celebration of the coming holiday ... launched a special offer on all these outfits. ... pioneer in the garment industry, PrettyTailor.com brings together art ... and small. The business carries quite a few in ...
    (Date:11/28/2014)... Nov. 28, 2014 (HealthDay News) -- People with diabetes face ... can help keep you healthy, an expert says. "With ... you,ll deal with the events, the family you,ll be visiting ... American Association of Diabetes Educators, said in an association news ... still be healthy." One idea is to make a ...
    (Date:11/28/2014)... 29, 2014 BambooFlooringChina.com has been recognized ... industry. Recently, the business has announced its new ... offering big discount on these new models. , Based ... by hands, without carpenter machines involved. It is crafted ... is great for do-it-yourselfers without hard work on installation, ...
    (Date:11/28/2014)... 2014 Dr. Diane Walder, one of ... the addition of Dr. Bridgit Nolan to her practice ... after having completed her dermatology residency at the University ... invited Dr. Nolan to join her practice ... cosmetic dermatology. Not only does Dr. Nolan strive to ...
    Breaking Medicine News(10 mins):Health News:BellasDress Offers A Big Surprise By Updating Its Cheap and Charming Cocktail Dresses 2Health News:2015 Wedding Dresses from PrettyTailor.com Available Now 2Health News:Holiday Eating Tips for People With Diabetes 2Health News:BambooFlooringChina.com Introduces Its New Strand Woven Bamboo Flooring Collection 2Health News:Dr. Diane Walder Welcomes New Cosmetic Dermatologist to Practice 2
    ... June 25 The ,Help is Here Express, bus tour ... June 29 - July 3 at various cities in order ... programs that provide prescription medicines for free or nearly free. ... to 2.9 percent a year ago, the Partnership for Prescription ...
    ... al. Study Finds Dose High Enough to Cause Adverse Effect ... , , ARLINGTON, Va., June 25 The ... has emerged that phthalates may not affect the reproductive development ... rats and mice. A study by McKinnell et al. ...
    ... 2009)AcademyHealth and the Robert Wood Johnson Foundation have ... outstanding potential to contribute to the field of ... recipients each receive $1,000 for registration and travel ... PHSR Interest Group Annual Meeting, June 28-July 1, ...
    ... used to help identify women with diabetes during pregnancy ... screen the general population for unrecognized diabetes and prediabetes, ... used to help identify women with diabetes during pregnancy ... screen the general population for unrecognized diabetes and prediabetes, ...
    ... Community , , Multi-Platform Campaign Incorporates PSAs, Integrated ... June 25 Today, leading U.S. media companies ... in response to AIDS and promote specific calls-to-action to prevent ... Greater Than AIDS - a multi-faceted ...
    ... or flight, hormone may play a role, researcher suggests ... experienced physical abuse as children are more likely to ... a Canadian study. , The University of Toronto researchers ... 49 percent increased risk of cancer in adulthood. Even ...
    Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 4Health News:New Scientific Evidence Suggests Humans Resistant to Phthalate Effect on Lab Rodents 2Health News:Glucose challenge test is accurate and economical for diabetes and prediabetes screening 2Health News:Glucose challenge test is accurate and economical for diabetes and prediabetes screening 3Health News:New Media-Led Effort Responds to AIDS Crisis in Black America 2Health News:New Media-Led Effort Responds to AIDS Crisis in Black America 3Health News:New Media-Led Effort Responds to AIDS Crisis in Black America 4Health News:New Media-Led Effort Responds to AIDS Crisis in Black America 5Health News:New Media-Led Effort Responds to AIDS Crisis in Black America 6Health News:Abused Kids Face Higher Cancer Risk 2
    The PYRAMETRIX PLUS instrument system is the next generation in design for disc space preparation and removal....
    CD HORIZON SEXTANT Rod Insertion System...
    Kerrison (Micro) Laminectomy Rongeur. 18 cm - 7 1/8, thick footplate, small handle, very delicate, 40 down-cutting, jaws 1 mm wide....
    Schlesinger Laminectomie Rongeur, golden springs. 15 cm - 6, with narrow footplate, large handle, 40 down-cutting, jaws 3 mm wide....
    Medicine Products: